CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	6.37M
Revenue (ttm)	-31.00K
Net Income (ttm)	-7.51M
Shares Out	32.68M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,493
Average Volume	124,129
Open	19.60
Previous Close	19.50
Day's Range	17.77 - 22.25
52-Week Range	5.00 - 30.90
Beta	0.23
RSI	65.86
Earnings Date	May 9, 2025

About CRISM Therapeutics

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX